Bryant C. Yung

Bryant C. Yung

Auto-generated profile, based on publicly available information

Bryant C. Yung

Laboratory of Molecular Imaging and Nanomedicine (LOMIN), National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH) , Bethesda, Maryland 20892, United States

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2017 in ACS Nano
Verified
Journal Article
Closed access
XHXiaolin Huang
Xiaolin Huang
YLYijing Liu
Yijing Liu
BYBryant Yung
Bryant Yung
Yonghua XiongYonghua Xiong
Yonghua Xiong
XCXiaoyuan Chen
Xiaoyuan Chen

28 February 2018 in Journal of Extracellular Vesicles
Verified
Journal Article
Open access
DWDionysios C Watson
Dionysios C Watson
BYBryant C. Yung
Bryant C. Yung
CBCristina Bergamaschi
Cristina Bergamaschi
BCBhabadeb Chowdhury
Bhabadeb Chowdhury
JBJenifer Bear
Jenifer Bear
GPGeorge N. Pavlakis
George N. Pavlakis
The development of extracellular vesicles (EV) for therapeutic applications is contingent upon the establishment of reproducible, scalable, and high‐throughput methods for the production and purification of clinical grade EV. Methods including ultracentrifugation (U/C), ultrafiltration, immunoprecipitation, and size‐exclusion chromatography (SEC) have been employed to isolate EV, each facing limitations such as efficiency, particle purity, lengthy processing time, and/or sample volume. We developed a cGMP‐compatible method for the scalable production, concentration, and isolation of EV through a strategy involving bioreactor culture, tangential flow filtration (TFF), and preparative SEC. We applied this purification method for the isolation of engineered EV carrying multiple complexes of a novel human immunostimulatory cytokine‐fusion protein, heterodimeric IL‐15 (hetIL‐15)/lactadherin. HEK293 cells stably expressing the fusion cytokine were cultured in a hollow‐fibre bioreactor. Conditioned medium was collected and EV were isolated comparing three procedures: U/C, SEC, or TFF + SEC. SEC demonstrated comparable particle recovery, size distribution, and hetIL‐15 density as U/C purification. Relative to U/C, SEC preparations achieved a 100‐fold reduction in ferritin concentration, a major protein‐complex contaminant. Comparative proteomics suggested that SEC additionally decreased the abundance of cytoplasmic proteins not associated with EV. Combination of TFF and SEC allowed for bulk processing of large starting volumes, and resulted in bioactive EV, without significant loss in particle yield or changes in size, morphology, and hetIL‐15/lactadherin density. Taken together, the combination of bioreactor culture with TFF + SEC comprises a scalable, efficient method for the production of highly purified, bioactive EV carrying hetIL‐15/lactadherin, which may be useful in targeted cancer immunotherapy approaches.

1 October 2017 in Journal of Controlled Release
Verified
Journal Article
Closed access
JKJihoon Kim
Jihoon Kim
BYBryant C. Yung
Bryant C. Yung
WKWon Jong Kim
Won Jong Kim
XCXiaoyuan Chen
Xiaoyuan Chen

15 June 2017 in ACS Nano
Verified
Journal Article
Closed access
JSJibin Song
Jibin Song
XYXiangyu Yang
Xiangyu Yang
ZYZhen Yang
Zhen Yang
LLLisen Lin
Lisen Lin
YLYijing Liu
Yijing Liu
XCXiaoyuan Chen
Xiaoyuan Chen

19 June 2019 in Journal of Extracellular Vesicles
Verified
Journal Article
Open access
AMAizea Morales‐Kastresana
Aizea Morales‐Kastresana
TMThomas A. Musich
Thomas A. Musich
Joshua WelshJoshua Welsh
Joshua Welsh
WTWilliam Telford
William Telford
TDThorsten Demberg
Thorsten Demberg
Jennifer JonesJennifer Jones
Jennifer Jones
Biological nanoparticles, including viruses and extracellular vesicles (EVs), are of interest to many fields of medicine as biomarkers and mediators of or treatments for disease. However, exosomes and small viruses fall below the detection limits of conventional flow cytometers due to the overlap of particle‐associated scattered light signals with the detection of background instrument noise from diffusely scattered light. To identify, sort, and study distinct subsets of EVs and other nanoparticles, as individual particles, we developed nanoscale Fluorescence Analysis and Cytometric Sorting (nanoFACS) methods to maximise information and material that can be obtained with high speed, high resolution flow cytometers. This nanoFACS method requires analysis of the instrument background noise (herein defined as the “reference noise”). With these methods, we demonstrate detection of tumour cell‐derived EVs with specific tumour antigens using both fluorescence and scattered light parameters. We further validated the performance of nanoFACS by sorting two distinct HIV strains to >95% purity and confirmed the viability (infectivity) and molecular specificity (specific cell tropism) of biological nanomaterials sorted with nanoFACS. This nanoFACS method provides a unique way to analyse and sort functional EV‐ and viral‐subsets with preservation of vesicular structure, surface protein specificity and RNA cargo activity.

1 June 2013 in Journal of Controlled Release
Verified
Journal Article
Closed access
MZMengzi Zhang
Mengzi Zhang
XZXiaoju Zhou
Xiaoju Zhou
BWBo Wang
Bo Wang
BYBryant C. Yung
Bryant C. Yung
LLLy J. Lee
Ly J. Lee
RLRobert Lee
Robert Lee